Measurement of serum concentrations of procollagen type I C-terminal propeptide may provide indirect diagnostic information on myocardial fibrosis extent in hypertensive heart disease.
Fibrous tissue accumulation is an integral feature of the adverse structural remodeling of cardiac tissue seen with hypertensive heart disease. Given the importance of fibrous tissue in leading to myocardial dysfunction and failure, noninvasive monitoring of myocardial fibrosis by use of serological markers of collagen turnover could prove a clinically useful tool, particularly given the potential for cardioprotective and cardioreparative pharmacological strategies. An emerging experimental and clinical experience holds promise for the use of radioimmunoassays of various serological markers of fibrillar collagen type I and type III turnover in arterial hypertension. More specifically, the measurement of serum concentrations of procollagen type I C-terminal propeptide (a peptide that is cleaved from procollagen type I during the synthesis of fibril-forming collagen type I) may provide indirect diagnostic information on both the extent of myocardial fibrosis and the ability of antihypertensive treatment to diminish collagen type I synthesis and reduce myocardial fibrosis. This approach represents an exciting and innovative strategy, and available data set the stage for larger trials, in which noninvasive measures of fibrosis in hypertensive heart disease could prove useful.
López et al. (Thu,) conducted a review in Hypertensive Heart Disease. Serological markers of collagen turnover (procollagen type I C-terminal propeptide) was evaluated. Measurement of serum concentrations of procollagen type I C-terminal propeptide may provide indirect diagnostic information on myocardial fibrosis extent in hypertensive heart disease.